RAG2 and sarcoma: While the fraction of neoantigens expressed did not differ significantly between sarcomas from Rag2−/− and Rag2+/− mice (Fig. 2e), tumors from immune-competent Rag2+/− mice had significantly lower expression of genes with neoantigenic mutations (Fig. 2f).